Clinical Registry & Platform
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed clinical updates.

Clinical Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

Clinical Coverage

Additional Clinical Updates

Rare Disease

FDA Approves lunsotogene parvec (OTARMENI) for OTOF-Related Hearing Loss: 80% Achieved PTA ≀70 dB HL

Sep 9|6 min read|By Dr. Lakshmi Venkatesan
Dermatology

risankizumab pediatric approval: weight‑based 55 mg for <40 kg in ages 6+

Sep 9|6 min read|By Dr. Divya Agarwal
Rare Disease

FDA Approves Tividenofusp Alfa for Neurologic Hunter Syndrome: 91% CSF Heparan Sulfate Reduction

Sep 9|6 min read|By Dr. Lakshmi Venkatesan
Endocrinology

Teplizumab (Tzield) FDA Expands Label to Delay C‑Peptide Decline in Pediatric Stage 3 T1D (0.13 pmol/mL)

Sep 9|6 min read|By Dr. Amit Desai
Oncology

Pembrolizumab FDA Approves First-Line for HER2+ Gastric/GEJ Cancer: KEYNOTE-811 PFS 10.9 vs 7.3 mo

Sep 8|5 min read|By Dr. Rahul Verma
Oncology

FDA Approves Inavolisib for PIK3CA‑Mutant HR+ HER2− Breast Cancer: Cuts Progression Risk 57% in INAVO120

Sep 8|7 min read|By Dr. Rahul Verma
Cardiology

DIGAMI: Insulin-Glucose Infusion Cuts Death Risk 25% in Diabetes with MI

Sep 8|6 min read|By Dr. Arjun Sharma
Rheumatology

Guselkumab Label Updated 06/04/2026; DISCOVER-2: 64% ACR20 in PsA

Sep 8|6 min read|By Dr. Deepak Nair
Oncology

FDA Approves sacituzumab govitecan for first-line mTNBC: Cuts Progression Risk 38% in ASCENT-03

Sep 7|6 min read|By Dr. Rahul Verma
Dermatology

FDA Adds Bemotrizinol to OTC Sunscreen Monograph

Sep 7|6 min read|By Dr. Divya Agarwal
Rare Disease

FDA Approves Zycubo for Menkes Disease: Cuts Death Risk 78%

Sep 7|5 min read|By Dr. Lakshmi Venkatesan
Anesthesiology

FDA Approves Cipepofol (CYPSEDO) for Induction of General Anesthesia

Sep 7|5 min read|By Dr. Neha Bansal
Oncology

FDA Approves pivekimab sunirine for BPDCN: CR/CRc 69.7% in Treatment‑Naïve CADENZA

Sep 6|6 min read|By Dr. Meera Pillai
Endocrinology

FDA Expands Tzield (teplizumab) Label to Stage 2 T1D ≄1 Year; TN-10 Shows HR 0.41 to Stage 3

Sep 6|6 min read|By Dr. Amit Desai
Oncology

FDA Approves durvalumab for BCG‑naïve NMIBC: DFS HR 0.68 in POTOMAC

Sep 6|5 min read|By Dr. Rahul Verma
Infectious Disease

Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations

Sep 6|6 min read|By Dr. Simran Kohli
Oncology

FDA Approves Capivasertib for HR+ HER2− Breast Cancer: Cuts Progression Risk 50% in CAPItello-291

Sep 6|7 min read|By Dr. Meera Pillai
Endocrinology

FDA Approves Tirzepatide (Zepbound) for Chronic Weight Management: 18% Mean Weight Loss in Trial

Sep 6|8 min read|By Dr. Amit Desai
Oncology

FDA Approves Tregzi for Matched-Donor HSCT: 78% vs 38.4% cGFS

Sep 5|6 min read|By Dr. Meera Pillai
Oncology

FDA Approves Palbociclib (Ibrance) for HR+ HER2+ Metastatic Breast Cancer: Cuts Progression Risk 25% (HR 0.75)

Sep 5|5 min read|By Dr. Rahul Verma
Oncology

FDA Approves vepdegestrant for ESR1‑mutant ER+ Breast Cancer: PFS HR 0.57

Sep 4|6 min read|By Dr. Rahul Verma
Rheumatology

Golimumab Immgolis Approved as Interchangeable for RA and UC

Sep 4|6 min read|By Dr. Deepak Nair
Dermatology

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

Sep 3|5 min read|By Dr. Divya Agarwal